Suzue Masaki, Wakabayashi Taku, Abe Kentaro, Hashimoto Ryuya, Fukuyama Hisashi, Yamamoto Yuki, Baba Keita, Ishida Yuichiro, Tsuboi Kotaro, Venkatesh Ramesh, Chhablani Jay, Ikuno Yasushi, Momenaei Bita, Kamei Motohiro, Yonekawa Yoshihiro, Oshima Yusuke, Gomi Fumi, Maeno Takatoshi
Department of Ophthalmology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Wakabayashi Eye Center, Nonoichi, Ishikawa, Japan.
Graefes Arch Clin Exp Ophthalmol. 2025 Jun 18. doi: 10.1007/s00417-025-06865-y.
To evaluate visual outcomes after vitrectomy based on preoperative visual acuity (VA) in eyes with myopic traction maculopathy (MTM) and explore the optimal timing for surgery.
Patients who underwent vitrectomy for MTM were categorized into four groups: preoperative vision of 20/25 or better (V1), worse than 20/25 to 20/50 (V2), 20/60 to 20/200 (V3), and worse than 20/200 (V4). The primary outcome was the postoperative VA at 12 months.
We included 193 eyes: V1 (12 eyes), V2 (77 eyes), V3 (83 eyes), and V4 (21 eyes). Postoperative VA significantly correlated with preoperative VA (R = 0.400, P < 0.001). Postoperative logarithm of the minimum angle of resolution VA was the best in V1 and worst in V4 (V1, 0.10 ± 0.26; V2, 0.19 ± 0.26; V3, 0.54 ± 0.44; and V4, 0.92 ± 0.54; P < 0.001). Visual improvement was highest in V4 and lowest in V1 (V1, 0.04 ± 0.26; V2, -0.12 ± 0.25; V3, -0.18 ± 0.41; and V4, -0.36 ± 0.44; P = 0.001). At 12 months, 83.3% of eyes in V1 achieved a postoperative VA of 20/25 or better, 90.9% of eyes in V2 achieved 20/50 or better, and 88.0% of eyes in V3 achieved 20/200 or better. Overall, 11.4% of eyes experienced a visual deterioration of three lines or more.
Vitrectomy generally maintains or improves vision in any group. Early surgery may help preserve good vision in eyes with good baseline vision and worsening symptoms; however, the risk of deterioration suggests it may not always be beneficial. Surgery at moderate visual impairment may offer a balanced benefit-risk ratio, avoiding surgery too early or too late.
根据术前视力评估高度近视性牵引性黄斑病变(MTM)患者玻璃体切除术后的视力结果,并探讨最佳手术时机。
接受MTM玻璃体切除术的患者分为四组:术前视力20/25或更好(V1组)、低于20/25至20/50(V2组)、20/60至20/200(V3组)以及低于20/200(V4组)。主要观察指标为术后12个月时的视力。
共纳入193只眼,V1组12只眼、V2组77只眼、V3组83只眼、V4组21只眼。术后视力与术前视力显著相关(R = 0.400,P < 0.001)。术后最小分辨角对数视力在V1组最佳,在V4组最差(V1组,0.10±0.26;V2组,0.19±0.26;V3组,0.54±0.44;V4组,0.92±0.54;P < 0.001)。视力改善程度在V4组最高,在V1组最低(V1组,0.04±0.26;V2组,-0.12±0.25;V3组,-0.18±0.41;V4组,-0.36±0.44;P = 0.001)。术后12个月时,V1组83.3%的患眼术后视力达到20/25或更好,V2组90.9%的患眼达到20/50或更好,V3组88.0%的患眼达到20/200或更好。总体而言,11.4%的患眼视力下降了3行或更多。
玻璃体切除术通常能维持或改善任何组别的视力。早期手术可能有助于保护基线视力良好且症状恶化的患眼的视力;然而,视力恶化的风险表明并非总是有益。中度视力损害时进行手术可能具有平衡的获益风险比,避免手术过早或过晚。